Abstract
edited by Robert S. Bedlack, Hiroshi Mitsumoto, Demos Medical Publishing, 2013, $65 Disease-modifying therapy for people with amyotrophic lateral sclerosis (ALS) is limited to riluzole, which has been available for 15 years and prolongs survival by 10% without appreciable benefit in function. Yet effective organization of clinical care, drawing on a wide variety of allied disciplines, can support patients and families through the course of the disease by maximizing function, limiting excess morbidity, and preparing patients for challenging decisions regarding treatment and end-of-life care. Amyotrophic Lateral Sclerosis: A Patient Care Guide for Clinicians is a state-of-the-art review of optimal ALS care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
